Paolo Ghia, MD, PhD, on the Chemo-Free, All-Oral Regimen of Ibrutinib Plus Venetoclax for First-Line CLL at ASCO 2021

News
Video

Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.

CancerNetwork® sat down with Paolo Ghia, MD, from the Universita Università Vita-Salute San Raffaele, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about the CAPTIVATE trial (NCT02910583) examining the chemotherapy-free regimen of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL). With the all-oral therapy regimen, patients experienced promising progression-free survival and overall survival.

Transcript:

This [regimen] is really opening a new way of treating patients with chronic lymphocytic leukemia, because so far we are used to continuing treatment, which [has] revolutionized the treatment in CLL. With the advent of oral therapies, [patients] indeed experienced increases in the progression-free survival and overall survival. Of course, having a fixed-duration treatment might be very beneficial for our patient because that would allow [us] to stop the treatment after a number of months, preventing the long-term adverse events, but also the possibility of the occurrence gene mutations and therefore resistance to the drugs.

Reference

Ghia P, Allan J, Siddiqi T et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol. 39;2021(suppl 15):7501. doi: 10.1200/JCO.2021.39.15_suppl.7501

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content